Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and Irinotecan in Recurrent High-grade Glioma
NCT02848794Phase 2Unknown
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- Jul 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in glioma, sponsored by First People's Hospital of Lianyungang City. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02848794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02848794.